REPLIMUNE GROUP INC
REPLNASDAQTrading Snapshot
- Day Range
- $13.50 – $13.80
- 52-Week Range
- $1.50 – $14.12
- Volume
- $5.10B
- Avg Volume
- $6.27B
- Shares Outstanding
- 84.0M
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $201M
- Last Q Revenue
- $48M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.39
- Dividend Yield
- —
Why Investors Own REPL
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About REPLIMUNE GROUP INC
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Transcript
Replimune Group, Inc. (REPL) Shareholder/Analyst Call August 6, 2026 4:30 PM EDTCompany ParticipantsArleen GoldenbergSushil Patel - CEO &...
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.
Replimune Group, Inc. (REPL) Shareholder/Analyst Call - Slideshow
2026-08-07. The following slide deck was published by Replimune Group, Inc.
Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted